ANIK — Anika Therapeutics, Inc.

Summary of Anika's Q4 and Year-End 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $30.6 million (flat year-over-year).
  • Commercial Channel Revenue: $13.3 million, up 22% driven by international OA pain management and Integrity.
  • OEM Channel Revenue: $17.3 million, down 12% year-over-year.
• Full Year 2025 Revenue: $112.8 million, a decline of 6% compared to 2024.
  • Commercial Channel Revenue: $48.4 million, up 15%.
  • OEM Channel Revenue: $64.4 million, down 17%.
• Gross Margin: Q4 gross margin increased to 63% from 56% year-over-year; full-year gross margin was 57%.
• Adjusted EBITDA: $4.5 million in Q4; $5.3 million for the full year, representing 5% of revenue.
• Operating Cash Flow: $11.2 million for the year, up from $5.4 million in 2024.
• Cash Position: Ended 2025 with $57.5 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Leadership Transition: Steve Griffin is the new CEO, succeeding Cheryl Blanchard, who remains as Executive Chair.
• Strategic Priorities:
  1. Revenue Growth: Focus on commercial channel growth, particularly in international OA pain management and Integrity.
  2. HA-based Innovation Pipeline: Advancements in Hyalofast, Cingal, and Integrity are ongoing, with regulatory submissions planned.
  3. Operational Execution: Improved manufacturing productivity and a streamlined organizational structure are expected to enhance profitability.
• Integrity Performance: Revenue more than doubled to approximately $6 million in 2025, with continued surgeon adoption and new product introductions.
• International Growth: Strong performance in international OA pain management, with a 28% revenue increase in Q4.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $114 million and $122.5 million (1% to 9% growth).
  • Commercial Channel: Projected growth of 10% to 20% year-over-year ($53 million to $58 million).
  • OEM Channel: Expected to be flat to down 5% ($61 million to $64.5 million).
• Adjusted EBITDA Guidance: Expected to be 5% to 10% of revenue, reflecting improved profitability from commercial growth and cost reductions.

4. Bad News, Challenges, or Points of Concern

• OEM Channel Decline: OEM revenue declined significantly due to pricing pressures in the U.S. OA pain management market.
• Regulatory Risks: Received a deficiency letter from the FDA regarding Hyalofast, which could delay approval.
• Market Dynamics: The U.S. pricing environment remains challenging, impacting OEM revenue and overall profitability.
• Operational Restructuring: While aimed at improving efficiency, restructuring may lead to transitional challenges and uncertainties.

5. Notable Q&A Insights

• Hyalofast Contribution: Anticipated revenue from Hyalofast in 2027 remains at $3 million, contingent on FDA approval.
• Gross Margin Expectations: Future gross margins are expected to normalize in the high 50s, reflecting operational capabilities.
• Free Cash Flow: Expected to be modestly in line with 2025 levels due to restructuring dynamics.
• International Market Potential: Continued market share gains and expansion into new markets are anticipated, with no specific underperforming countries identified.
• Integrity Growth: Strong double-digit growth is expected for Integrity in 2026, although not at the same percentage increase as 2025.

Overall, Anika's performance in 2025 showed resilience in its commercial channel, particularly internationally, while facing challenges in its OEM segment. The company is focused on strategic growth initiatives and operational improvements as it moves into 2026.